Roles of ceramide synthase and ceramide clearence genes in nilotinib-induced cell death in chronic myeloidleukemia cells

References

• Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408–2417.
   PubMed Web of Science ®Google Scholar
• Copland M, Pellicano F, Richmond L, et al. BMS-214662 potently induces apoptosis of chronic myeloid leukemia stem and progenitor cells and synergizes with tyrosine kinase inhibitors. Blood 2008;111:2843–2853.
   PubMed Web of Science ®Google Scholar
• Van Etten RA. Mechanisms of transformation by the BCR-ABL oncogene: new perspectives in the post-imatinib era. Leuk Res 2004;28(Suppl. 1):S21–s28.
   PubMed Web of Science ®Google Scholar
• Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005;5:172–183.
   PubMed Web of Science ®Google Scholar
• Koca E, Haznedaroglu I. Imatinib mesylate and the management of chronic myeloid leukemia (CML). Turk J Haematol 2005;22:161–172.
   PubMedGoogle Scholar
• Jabbour E, Cortes J, Giles F, Kantarjian H. Current perspectives on the treatment of patients with chronic myeloid leukemia: an individualized approach to treatment. Cancer J 2007;13:357–365.
   PubMed Web of Science ®Google Scholar
• Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer 2007; 7:441–453.
   PubMed Web of Science ®Google Scholar
• Bonhoure E, Lauret A, Barnes DJ, et al. Sphingosine kinase-1 is a downstream regulator of imatinib-induced apoptosis in chronic myeloid leukemia cells. Leukemia 2008;22:971–979.
   PubMed Web of Science ®Google Scholar
• Baran Y, Ural AU, Gunduz U. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells. Hematology 2007;12:497–503.
   PubMed Web of Science ®Google Scholar
• Zhou J. Multi-drug resistance in cancer. New YorkSpringer2009.
   Google Scholar
• Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876–880.
   PubMed Web of Science ®Google Scholar
• Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia 2004;18:401–408.
   PubMed Web of Science ®Google Scholar
• McFarland KL, Wetzstein GA. Chronic myeloid leukemia therapy: focus on second-generation tyrosine kinase inhibitors. Cancer Control 2009;16:132–140.
   PubMed Web of Science ®Google Scholar
• Deininger MW. Nilotinib. Clin Cancer Res 2008;14:4027–4031.
   PubMed Web of Science ®Google Scholar
• Pavlovsky C, Kantarjian H, Cortes JE. First-line therapy for chronic myeloid leukemia: past, present, and future. Am J Hematol 2009;84:287–293.
   PubMed Web of Science ®Google Scholar
• Futerman AH, Hannun YA. The complex life of simple sphingolipids. EMBO Rep 2004;5:777–782.
   PubMed Web of Science ®Google Scholar
• Nica AF, Tsao CC, Watt JC, et al. Ceramide promotes apoptosis in chronic myelogenous leukemia-derived K562 cells by a mechanism involving caspase-8 and JNK. Cell Cycle 2008;7:3362–3370.
   PubMed Web of Science ®Google Scholar
• Ogretmen B, Hannun YA. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat Rev Cancer 2004; 4:604–616.
   PubMed Web of Science ®Google Scholar
• Reynolds CP, Maurer BJ, Kolesnick RN. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett 2004;206:169–180.
   PubMed Web of Science ®Google Scholar
• Fox TE, Finnegan CM, Blumenthal R, Kester M. The clinical potential of sphingolipid-based therapeutics. Cell Mol Life Sci 2006;63:1017–1023.
   PubMed Web of Science ®Google Scholar
• Modrak DE, Gold DV, Goldenberg DM. Sphingolipid targets in cancer therapy. Mol Cancer Ther 2006;5:200–208.
   PubMed Web of Science ®Google Scholar
• Verheij M, Bose R, Lin XH, et al. Requirement for ceramide-initiated SAPK/JNK signalling in stress-induced apoptosis. Nature 1996;380:75–79.
   PubMed Web of Science ®Google Scholar
• Senchenkov A, Litvak DA, Cabot MC. Targeting ceramide metabolism–a strategy for overcoming drug resistance. J Natl Cancer Inst 2001;93:347–357.
   PubMed Web of Science ®Google Scholar
• Baran Y, Salas A, Senkal CE, et al. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J Biol Chem 2007;282:10922–10934.
   PubMed Web of Science ®Google Scholar
• Zhao L, Au JL, Wientjes MG. Comparison of methods for evaluating drug-drug interaction. Front Biosci (Elite Ed) 2010;2:241–249.
   PubMedGoogle Scholar
• Ekiz HA, Can G, Baran Y. Nilotinib significantly induces apoptosis in imatinib resistant K562 cells, as effectively as in parental sensitive counterparts. Hematology 2010;15:33–38.
   PubMed Web of Science ®Google Scholar
• Kartal M, Saydam G, Sahin F, Baran Y. Increasing intracellular generation or accumulation of ceramides increased cytotoxic effects of resveratrol in human K562 chronic myeloid leukemia cells. Haematologica 2009;94(Suppl. 2): Abstract 1241.
   Google Scholar
• Falluel-Morel A, Aubert N, Vaudry D, et al. Opposite regulation of the mitochondrial apoptotic pathway by C2-ceramide and PACAP through a MAP-kinase-dependent mechanism in cerebellar granule cells. J Neurochem 2004; 91:1231–1243.
   PubMed Web of Science ®Google Scholar
• De Maria R, Lenti L, Malisan F, et al. Requirement for GD3 ganglioside in CD95- and ceramide-induced apoptosis. Science 1997;277:1652–1655.
   PubMed Web of Science ®Google Scholar
• Pannu R, Singh AK, Singh I. A novel role of lactosylceramide in the regulation of tumor necrosis factor alpha-mediated proliferation of rat primary astrocytes. J Biol Chem 2005;280: 13742–13751.
   PubMed Web of Science ®Google Scholar
• Burow ME, Weldon CB, Collins-Burow MB, et al. Cross-talk between phosphatidylinositol 3-kinase and sphingomyelinase pathways as a mechanism for cell survival/death decisions. J Biol Chem 2000;275:9628–9635.
   PubMed Web of Science ®Google Scholar
• Cakir Z, Saydam G, Sahin F, Baran Y. The roles of bioactive sphingolipids in resveratrol-induced apoptosis in HL60: acute myeloid leukemia cells. J Cancer Res Clin Oncol 2011;137: 279–286.
   PubMed Web of Science ®Google Scholar
• et al. Weisberg E, Manley P, Mestan J, et al, AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br J Cancer 2006; 94:1765–1769.
   PubMed Web of Science ®Google Scholar
• Fava C, Kantarjian HM, Jabbour E, et al. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Blood 2009;113:5058–5063.
   PubMed Web of Science ®Google Scholar
• Plosker GL, Robinson DM. Nilotinib. Drugs 2008;68:449–459; discussion 460–441.
   PubMed Web of Science ®Google Scholar
• Deremer DL, Ustun C, Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther 2008;30:1956–1975.
   PubMed Web of Science ®Google Scholar
• Beckham TH, Elojeimy S, Cheng JC, et al. Targeting sphingolipid metabolism in head and neck cancer: rational therapeutic potentials. Expert Opin Ther Targets 2010;14: 529–539.
   PubMed Web of Science ®Google Scholar
• Cuvillier O, Ader I, Bouquerel P, et al. Activation of sphingosine kinase-1 in cancer: implications for therapeutic targeting. Curr Mol Pharmacol 2010;3:53–65.
   PubMedGoogle Scholar
• Takabe K, Paugh SW, Milstien S, Spiegel S. ‘Inside-out’ signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 2008;60:181–195.
   PubMed Web of Science ®Google Scholar
• Pchejetski D, Doumerc N, Golzio M, et al. Chemosensitizing effects of sphingosine kinase-1 inhibition in prostate cancer cell and animal models. Mol Cancer Ther 2008;7:1836–1845.
   PubMed Web of Science ®Google Scholar
• Xie P, Shen YF, Shi YP, et al. Overexpression of glucosylceramide synthase in associated with multidrug resistance of leukemia cells. Leuk Res 2008;32:475–480.
   PubMed Web of Science ®Google Scholar
• Liu YY, Han TY, Giuliano AE, Cabot MC. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J 2001;15:719–730.
   PubMed Web of Science ®Google Scholar
• Olshefski RS, Ladisch S. Glucosylceramide synthase inhibition enhances vincristine-induced cytotoxicity. Int J Cancer 2001;93:131–138.
   PubMed Web of Science ®Google Scholar
• Morjani H, Aouali N, Belhoussine R, Veldman RJ, Levade T, Manfait M. Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets. Int J Cancer 2001;94:157–165.
   PubMed Web of Science ®Google Scholar
• Dijkhuis AJ, Klappe K, Jacobs S, et al. PDMP sensitizes neuroblastoma to paclitaxel by inducing aberrant cell cycle progression leading to hyperploidy. Mol Cancer Ther 2006; 5:593–601.
   PubMed Web of Science ®Google Scholar
• Radin NS. Poly-drug cancer therapy based on ceramide. Eksp Onkol 2004;26:3–10.
   PubMed Web of Science ®Google Scholar